Global Pancreatic Cancer Diagnostics Market was valued at approximately USD 3,562.51 million in 2020 and is expected to witness a revenue of USD 5,999.78 million in 2027, with a CAGR of 8.9% over the forecast period. Pancreatic cancer will begin in tissues of pancreas. Pancreas secretes enzymes which helps in the digestion and manage blood sugar levels. pancreatic cancer diagnostics market rapidly spreads to the nearby organs. Often it can be diagnosed at early stages in people with pancreatic cyst or family history of pancreatic cancer. Most common sign of pancreatic cancer is diabetes which occurs along with loss of weight, pain in the upper abdomen and that spreads to the back. This development can be attributed to patients’ desire for comprehensive therapy and the availability of enhanced instruments and knowledge. Due to an increase in the consumption of alcohol and cigarettes, as well as changes in lifestyle, the market for pancreatic cancer diagnostics is growing. Furthermore, widespread use of high-cost medications such as Abraxane injection and Gemzar to treat pancreatic cancer boosts the market. Technologies for timely diagnosis of pancreatic cancer are yet to develop at a full stretch which may results in early diagnosis of advanced stage of pancreatic cancer and can provide rightful treatment. Moreover, major players are getting collaborated with government and other social responsible agencies to improve the patient accessibility and affordability towards the treatments and diagnosis. For example, Illumina, Inc. has launched a venture called GRAIL along with Billgates and Jeff Bezos as investors with $100 Mn to focus on the blood based cancer screening for early and timely diagnosis of the common tumours through simple laboratory tests.